Market Currents
Amylin (AMLN) +9% to $30.75 following news it's being bought by Bristol-Myers Squibb (BMY -0.1%)...
-
Monday, July 2, 2012, 8:48 AM ETAmylin (AMLN) +9% to $30.75 following news it's being bought by Bristol-Myers Squibb (BMY -0.1%) and AstraZeneca (AZN -0.1%) in a 31/share deal worth $7B. Bernstein analyst Tim Anderson says BMY and AZN are the most logical buyers, although he doesn't think the transaction will significantly alter the financial outlook for either company.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
